Misoprostol modulates cytokine expression through a cAMP pathway : Potential therapeutic implication for liver disease

Copyright © 2015 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 161(2015), 2 vom: 15. Dez., Seite 291-9
1. Verfasser: Gobejishvili, Leila (VerfasserIn)
Weitere Verfasser: Ghare, Smita, Khan, Rehan, Cambon, Alexander, Barker, David F, Barve, Shirish, McClain, Craig, Hill, Daniell
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2015
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. CREB ChIP Inflammation Liver disease NFκB cAMP mehr... Anti-Ulcer Agents Cytokines Lipopolysaccharides Tumor Necrosis Factor-alpha Misoprostol 0E43V0BB57 Interleukin-10 130068-27-8 Cyclic AMP E0399OZS9N
LEADER 01000naa a22002652 4500
001 NLM253123380
003 DE-627
005 20231224165545.0
007 cr uuu---uuuuu
008 231224s2015 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2015.09.008  |2 doi 
028 5 2 |a pubmed24n0843.xml 
035 |a (DE-627)NLM253123380 
035 |a (NLM)26408955 
035 |a (PII)S1521-6616(15)30041-3 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Gobejishvili, Leila  |e verfasserin  |4 aut 
245 1 0 |a Misoprostol modulates cytokine expression through a cAMP pathway  |b Potential therapeutic implication for liver disease 
264 1 |c 2015 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 14.03.2016 
500 |a Date Revised 08.04.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2015 Elsevier Inc. All rights reserved. 
520 |a Dysregulated cytokine metabolism plays a critical role in the pathogenesis of many forms of liver disease, including alcoholic and non-alcoholic liver disease. In this study we examined the efficacy of Misoprostol in modulating LPS-inducible TNFα and IL-10 expression in healthy human subjects and evaluated molecular mechanisms for Misoprostol modulation of cytokines in vitro. Healthy subjects were given 14day courses of Misoprostol at doses of 100, 200, and 300μg four times a day, in random order. Baseline and LPS-inducible cytokine levels were examined ex vivo in whole blood at the beginning and the end of the study. Additionally, in vitro studies were performed using primary human PBMCs and the murine macrophage cell line, RAW 264.7, to investigate underlying mechanisms of misoprostol on cytokine production. Administration of Misoprostol reduced LPS inducible TNF production by 29%, while increasing IL-10 production by 79% in human subjects with no significant dose effect on ex vivo cytokine activity; In vitro, the effect of Misoprostol was largely mediated by increased cAMP levels and consequent changes in CRE and NFκB activity, which are critical for regulating IL-10 and TNF expression. Additionally, chromatin immunoprecipitation (ChIP) studies demonstrated that Misoprostol treatment led to changes in transcription factor and RNA Polymerase II binding, resulting in changes in mRNA levels. In summary, Misoprostol was effective at beneficially modulating TNF and IL-10 levels both in vivo and in vitro; these studies suggest a potential rationale for Misoprostol use in ALD, NASH and other liver diseases where inflammation plays an etiologic role 
650 4 |a Journal Article 
650 4 |a Randomized Controlled Trial 
650 4 |a Research Support, N.I.H., Extramural 
650 4 |a Research Support, U.S. Gov't, Non-P.H.S. 
650 4 |a CREB 
650 4 |a ChIP 
650 4 |a Inflammation 
650 4 |a Liver disease 
650 4 |a NFκB 
650 4 |a cAMP 
650 7 |a Anti-Ulcer Agents  |2 NLM 
650 7 |a Cytokines  |2 NLM 
650 7 |a Lipopolysaccharides  |2 NLM 
650 7 |a Tumor Necrosis Factor-alpha  |2 NLM 
650 7 |a Misoprostol  |2 NLM 
650 7 |a 0E43V0BB57  |2 NLM 
650 7 |a Interleukin-10  |2 NLM 
650 7 |a 130068-27-8  |2 NLM 
650 7 |a Cyclic AMP  |2 NLM 
650 7 |a E0399OZS9N  |2 NLM 
700 1 |a Ghare, Smita  |e verfasserin  |4 aut 
700 1 |a Khan, Rehan  |e verfasserin  |4 aut 
700 1 |a Cambon, Alexander  |e verfasserin  |4 aut 
700 1 |a Barker, David F  |e verfasserin  |4 aut 
700 1 |a Barve, Shirish  |e verfasserin  |4 aut 
700 1 |a McClain, Craig  |e verfasserin  |4 aut 
700 1 |a Hill, Daniell  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 161(2015), 2 vom: 15. Dez., Seite 291-9  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:161  |g year:2015  |g number:2  |g day:15  |g month:12  |g pages:291-9 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2015.09.008  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 161  |j 2015  |e 2  |b 15  |c 12  |h 291-9